Nuvectis Pharma Inc. reported a net loss of $6.05 million for the three months ended March 31 2026, a 14% increase from the $5.33 million loss recorded in the same period a year earlier. Diluted earnings per share fell to $0.26 from $0.27 in Q1 2025, reflecting higher operating expenses. Cash and cash equivalents were $25.1 million at March 31, down $6.5 million from $31.6 million at the end of 2025, driven by a $4.1 million increase in research and development costs and a $0.3 million rise in general and administrative expenses.
The company’s quarterly cash burn of $6.5 million translates into an estimated runway of roughly 18 months at the current spending rate, a figure management reiterated in its commentary. The burn is largely attributable to intensified investment in the NXP900 Phase 1b program, which has seen enrollment grow at leading U.S. sites for both monotherapy and combination cohorts.
The modest decline in diluted EPS is largely a consequence of the $0.4 million rise in R&D spending—largely driven by increased manufacturing costs, employee compensation, and clinical trial expenditures—and the $0.3 million increase in G&A costs, which were largely due to higher professional and consulting fees. Because the company is still in the early stages of its pipeline, the higher expenses are expected to be offset by future clinical milestones.
“2026 is off to a good start for Nuvectis as we advance the NXP900 Phase 1b clinical program which continues to enroll patients at top sites in the US in both the monotherapy and combination arms of the program,” said Chairman and CEO Ron Bentsur. “We are excited for what’s ahead in 2026 and expect a preliminary data readout from the NXP900 Phase 1b study in the summer.”
With the company’s cash position tightening, the focus remains on disciplined spending while pursuing the next data readout. The upcoming summer 2026 preliminary results will be a key catalyst for assessing the viability of NXP900 as a potential therapeutic option for non‑small cell lung cancer, and will inform the company’s longer‑term funding strategy and potential partnership opportunities.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.